Skip to main content

Advertisement

P085: Surveillance of drug-resistant Salmonella sp and Shigella sp infections in Rwanda

Introduction

Salmonella sp. and Shigella sp infections are public health threat worldwide, particularly in Sub-Saharan Africa including in Rwanda. This study was done to identify Salmonella sp. and Shigella sp. currently circulating in Rwanda and determine their drug susceptibility pattern.

Objectives

To determine the prevalence of Salmonella spp. and Shigella spp. strains circulating in Rwanda and their susceptibilty pattern in Rwanda.

Methods

196 blood and 24 stool specimens from patients were analyzed in Laboratory of Rwanda for culture isolation, identification and drug-sensitivity testing.

Results

91 (92.2 %) of them were identified as Salmonella enterica serovar Typhi, 10 were Shigella sp. The isolates were subsequently subjected to antibiotic susceptibility tests and the strains of S.Typhi isolates were found to be susceptible to cefotaxime (100%), and ciprofloxacin (97.9 %) and resistant to nalidixic acid (89.4%), cotrimoxazole (87.2%). With regard to Shigella infections, the antibiotics which showed 100% susceptibility to all species identified were ciprofloxacine, cefotaxime, ceftazidine.

Conclusion

The prevalent Salmonella strain circulating in Rwanda is S.Typhi and two most useful drugs of choice to treat Salmonella sp. and Shigella sp. infections in Rwanda are cefotaxime and ciprofloxacin.

Disclosure of interest

None declared

Author information

Correspondence to JB Gatabazi.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Public Health
  • Infectious Disease
  • Cefotaxime
  • Susceptibility Test
  • Nalidixic Acid